These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26775862)

  • 1. Dynamics and control of a mathematical model for metronomic chemotherapy.
    Ledzewicz U; Amini B; Schättler H
    Math Biosci Eng; 2015 Dec; 12(6):1257-75. PubMed ID: 26775862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy.
    Schättler H; Ledzewicz U; Amini B
    J Math Biol; 2016 Apr; 72(5):1255-80. PubMed ID: 26089097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On optimal chemotherapy with a strongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth.
    Ledzewicz U; Olumoye O; Schättler H
    Math Biosci Eng; 2013 Jun; 10(3):787-802. PubMed ID: 23906150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
    Arora G; Bairagi N; Chatterjee S
    Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
    Poleszczuk J; Bodnar M; Foryś U
    Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
    Ledzewicz U; Schättler H
    Cancer Lett; 2017 Aug; 401():74-80. PubMed ID: 28323033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis.
    Ledzewicz U; Schättler H
    J Theor Biol; 2008 May; 252(2):295-312. PubMed ID: 18371982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Chemotherapeutic Anti-cancer Treatment and the Tumor Microenvironment: An Analysis of Mathematical Models.
    Ledzewicz U; Schaettler H
    Adv Exp Med Biol; 2016; 936():209-223. PubMed ID: 27739050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
    Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic scheduling: the future of chemotherapy?
    Gasparini G
    Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metronomic chemotherapy in 2011: update and perspectives].
    Benbrahim Z; Massard C; El Mesbahi O
    Bull Cancer; 2011 Dec; 98(12):1447-54. PubMed ID: 22146261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
    Gnoni A; Silvestris N; Licchetta A; Santini D; Scartozzi M; Ria R; Pisconti S; Petrelli F; Vacca A; Lorusso V
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):46-61. PubMed ID: 25656744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
    André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
    Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.